Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cyclin D2 controls B cell progenitor numbers.

Azim Mohamedali1, Inês Soeiro, Nicholas C Lea

  • 1Leukaemia Sciences, Guy's, King's, St. Thomas' School of Medicine, Rayne Institute, 123 Coldharbour Lane, London SE5 9RS, UK. nicholas.s.thomas@kcl.ac.uk

Journal of Leukocyte Biology
|November 13, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Expression of Concern: FOXM1 Confers Acquired Cisplatin Resistance in Breast Cancer Cells.

Molecular cancer research : MCR·2026
Same author

Expression of Concern: The p38 MAPK-MK2 Axis Regulates E2F1 and FOXM1 Expression after Epirubicin Treatment.

Molecular cancer research : MCR·2026
Same author

Retraction: Senescent Stromal Cells Promote Cancer Resistance through SIRT1 Loss-Potentiated Overproduction of Small Extracellular Vesicles.

Cancer research·2026
Same author

Expression of Concern: SIRT Inhibitors Induce Cell Death and p53 Acetylation through Targeting Both SIRT1 and SIRT2.

Molecular cancer therapeutics·2026
Same author

Expression of Concern: Gefitinib (Iressa) Represses FOXM1 Expression via FOXO3a in Breast Cancer.

Molecular cancer therapeutics·2026
Same author

Expression of Concern: The Transcription Factor FOXO3a is a Crucial Cellular Target of Gefitinib (Iressa) in Breast Cancer Cells.

Molecular cancer therapeutics·2026

Cyclin D2 is crucial for producing B cell progenitors, impacting their early development. Its absence reduces progenitor numbers, but other cyclins may compensate in mature B cells.

Area of Science:

  • Immunology
  • Cell Biology
  • Molecular Biology

Background:

  • Cyclin D2 plays a role in B cell proliferation and differentiation.
  • Cyclin D2 deficiency in mice leads to a lack of CD5+ (B1) B lymphocytes.
  • The precise role of cyclin D2 in early B cell development is not fully understood.

Purpose of the Study:

  • To investigate the role of cyclin D2 in B cell progenitor production and development.
  • To determine if cyclin D2 deficiency affects progenitor cell numbers and maturation.
  • To explore potential compensatory mechanisms for cyclin D2 loss in B cell development.

Main Methods:

  • Analysis of bone marrow cells from cyclin D2 knockout (cyclin D2-/-) and wild-type (cyclin D2+/+) mice.
  • Flow cytometry to assess progenitor cell populations (Sca1+B220+) and maturation markers (CD19).

Related Experiment Videos

  • Clonal analysis of bone marrow progenitors.
  • Co-immunoprecipitation assays to study cyclin-dependent kinase interactions.
  • Western blotting to assess retinoblastoma protein phosphorylation.

    • Main Results:

    • Cyclin D2-/- mice exhibit a 50% reduction in B cell progenitors (Sca1+B220+) in bone marrow.
    • Progenitors from cyclin D2-/- mice show less mature phenotypes (CD19lo) compared to controls (CD19Hi).
    • The number of mature B2 B cells remains unchanged in cyclin D2-/- mice, suggesting compensation.
    • Cyclin D3, not cyclin D1, interacts with CDK6 in cyclin D2-/- bone marrow cells, indicating a compensatory role.

    Conclusions:

    • Cyclin D2 is rate-limiting for the production of B lymphoid progenitor cells.
    • B cell progenitor proliferation is independent of B cell receptor (BCR) signaling in the context of cyclin D2 deficiency.
    • Cyclin D3 can compensate for the loss of cyclin D2 in regulating progenitor cell proliferation and maturation via CDK6.